{Reference Type}: Journal Article
{Title}: Siderophore-Conjugated Antifungals: A Strategy to Potentially Cure Fungal Infections.
{Author}: Lakshminarayanan K;Murugan D;Venkatesan J;Vasanthakumari Thirumalaiswamy H;Gadais C;Rangasamy L;
{Journal}: ACS Infect Dis
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 21
{Factor}: 5.578
{DOI}: 10.1021/acsinfecdis.4c00046
{Abstract}: Fungi pose a global threat to humankind due to the increasing emergence of multi-drug-resistant fungi. There is a rising incidence of invasive fungal infections. Due to the structural complexity of fungal cell membranes, only a few classes of antifungal agents are effective and have been approved by the U.S. FDA. Hence, researchers globally are focusing on developing novel strategies to cure fungal infections. One of the potential strategies is the "Trojan horse" approach, which uses the siderophore-mediated iron acquisition (SIA) system to scavenge iron to deliver potent antifungal agents for therapeutics and diagnostics. These siderophore conjugates chelate to iron and are taken up through siderophore-iron transporters, which are overexpressed exclusively on microbes such as bacteria or fungi, but not mammalian cells. Our comprehensive review delves into recent advancements in the design of siderophore-conjugated antifungal agents to gain fungal cell entry. Notably, our focus extends to unraveling the intricate relationship between the structure of natural siderophores or siderophore-like molecules and the resulting antifungal activity. By exploring these design strategies, we aim to contribute to the ongoing discourse on combating drug-resistant fungal infections and advancing the landscape of antifungal theranostics.